The company expects to provide results from a 68-week study in people with obesity and osteoarthritis of the knee in 2025, according to fourth-quarter earnings slides on its website
This peptide-pathway genetic testing approach differs from standard pharmacogenomic screening and identifies whether you are a responder, slow responder, or candidate for dual-peptide therapy (combining semaglutide with tirzepatide)
Multi-receptor agonists are advancing fast, but so are gut Great post, but the idea that more receptors = better hasnt really held up when you look at the actual data
Personalizing Treatment Based on DEXA Results Healthcare providers can use DEXA scan data to tailor GLP-1 treatment plans, including dietary, exercise, or medication adjustments to optimize body composition outcomes
How this differs from microdosing Splitting your full weekly dose into two injections is not microdosing
Retatrutide Injection obesity and type 2 diabetes drug therapy in India
